- Home
- AKTX vs RDI Comparison
AKTX vs RDI Comparison
Compare AKTX & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- RDI
- Stock Information
- Founded
- AKTX N/A
- RDI 1937
- Country
- AKTX United States
- RDI United States
- Employees
- AKTX N/A
- RDI N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- RDI Movies/Entertainment
- Sector
- AKTX Health Care
- RDI Consumer Discretionary
- Exchange
- AKTX Nasdaq
- RDI Nasdaq
- Market Cap
- AKTX 35.7M
- RDI 35.7M
- IPO Year
- AKTX N/A
- RDI N/A
- Fundamental
- Price
- AKTX $0.76
- RDI $1.53
- Analyst Decision
- AKTX Strong Buy
- RDI
- Analyst Count
- AKTX 2
- RDI 0
- Target Price
- AKTX $3.30
- RDI N/A
- AVG Volume (30 Days)
- AKTX 91.6K
- RDI 46.7K
- Earning Date
- AKTX 08-13-2025
- RDI 11-13-2025
- Dividend Yield
- AKTX N/A
- RDI N/A
- EPS Growth
- AKTX N/A
- RDI N/A
- EPS
- AKTX N/A
- RDI N/A
- Revenue
- AKTX N/A
- RDI $219,213,000.00
- Revenue This Year
- AKTX N/A
- RDI $5.21
- Revenue Next Year
- AKTX N/A
- RDI $11.45
- P/E Ratio
- AKTX N/A
- RDI N/A
- Revenue Growth
- AKTX N/A
- RDI 7.59
- 52 Week Low
- AKTX $0.57
- RDI $1.17
- 52 Week High
- AKTX $3.85
- RDI $1.89
- Technical
- Relative Strength Index (RSI)
- AKTX 37.47
- RDI 52.53
- Support Level
- AKTX $0.75
- RDI N/A
- Resistance Level
- AKTX $0.89
- RDI $1.57
- Average True Range (ATR)
- AKTX 0.07
- RDI 0.07
- MACD
- AKTX 0.01
- RDI -0.06
- Stochastic Oscillator
- AKTX 57.86
- RDI 93.87
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.